Top

Published in:

01-01-2017 | Original Article

Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women

Authors: Tomohiko Urano, Masataka Shiraki, Tatsuhiko Kuroda, Shiro Tanaka, Kazuhiro Uenishi, Satoshi Inoue

Published in: Journal of Bone and Mineral Metabolism | Issue 1/2017

Abstract

Decline of body weight and body mass index (BMI) with aging is a major risk factor for osteoporosis and fracture, suggesting that treatment for osteoporosis may affect body composition. However, the effects of treatment for osteoporosis on body composition are not well known. The present study aimed to identify the relationship between raloxifene treatment and body composition markers. We measured bone mineral density (BMD), body composition, and bone remodeling markers in 236 Japanese postmenopausal women with raloxifene treatment (N = 50) and without treatment by any osteoporosis drug (N = 186) for 5 years and analyzed the relationship of these with BMD, BMI, body weight, and biochemical markers. The mean (SD) age of the participants was 65.5 (9.3) years. Percent-changes in body weight and BMI were significantly different between women taking raloxifene and those not taking any osteoporosis drugs (P = 0.03 and 0.048, respectively). Raloxifene treatment was a significant independent determinant of body weight and BMI. Long-term treatment with raloxifene prevents age-related weight loss.

Samson MM, Meeuwsen IBAE, Crowe A, Dessens JAG, Duursma SA, Verhaar HJJ (2010) Differences in variables of muscle strength and functional mobility in healthy subjects in relation to age, height and body weight. Age Ageing 29:235–242CrossRef

Kallman DA, Plato CC, Tobin JD (1990) The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol 45:M82–M88CrossRefPubMed

Panotopoulos G, Raison J, Ruiz JC, Guy-Grand B, Basdevant A (1997) Weight gain at the time of menopause. Hum Reprod 12:126–133CrossRefPubMed

Di Carlo C, Tommaselli GA, Sammantino A, Bifulco G, Nasti A, Nappi C (2004) Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause 11:466–473CrossRefPubMed

Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L (1984) Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gothenburg. Sweden. Br Med J (Clin Res Ed) 289:1257–1261CrossRef

Hagberg JM, Zmuda JM, McCole SD, Rodgers KS, Wilund KR, Moore GE (2000) Determinants of body composition in postmenopausal women. J Gerontol A Biol Sci Med Sci 55:M607–M612CrossRefPubMed

Phillips SK, Rook KM, Siddle NC, Bruce SA, Woledge RC (1993) Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Lond) 84:95–98CrossRef

Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738CrossRefPubMed

Greeves JP, Cable NT, Reilly T, Kingsland C (1999) Changes in muscle strength in women following the menopause: a longitudinal assessment of the efficacy of hormone replacement therapy. Clin Sci (Lond) 97:79–84CrossRef

10.

Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMed

11.

Khovidhunkit W, Shoback DM (1999) Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 130:431–439CrossRefPubMed

12.

Ott SM, Oleksik A, Lu Y, Harper K, Lips P (2002) Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 17:341–348CrossRefPubMed

13.

Jolly EE, Bjarnason NH, Neven P et al (2003) Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 10:337–344CrossRefPubMed

14.

Ivergård M, Ström O, Borgström F, Burge RT, Tosteson AN, Kanis J (2010) Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone 47:966–974CrossRefPubMed

15.

Silverman SL, Chines AA, Kendler DL et al (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23:351–363CrossRefPubMed

16.

Jacobsen DE, Samson MM, Emmelot-Vonk MH, Verhaar HJ (2010) Raloxifene and body composition and muscle strength in postmenopausal women: a randomized, double-blind, placebo-controlled trial. Eur J Endocrinol 162:371–376CrossRefPubMed

17.

Francucci CM, Daniele P, Iori N, Camilletti A, Massi F, Boscaro M (2005) Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women. J Endocrinol Invest 28:623–631CrossRefPubMed

18.

Shiraki M, Kuroda T, Shiraki Y, Aoki C, Sasaki K, Tanaka S (2010) Effects of bone mineral density of the lumbar spine and prevalent vertebral fractures on the risk of immobility. Osteoporos Int 21:1545–1551CrossRefPubMed

19.

Urano T, Shiraki M, Ouchi Y, Inoue S (2012) Association of circulating sclerostin levels with fat mass and metabolic disease-related markers in Japanese postmenopausal women. J Clin Endocrinol Metab 97:E1473–E1477CrossRefPubMed

20.

Uenishi K, Ishida H, Nakamura K (2008) Development of a simple food frequency questionnaire to estimate intakes of calcium and other nutrients for the prevention and management of osteoporosis. J Nutr Sci Vitaminol (Tokyo) 54:25–29CrossRef

21.

Han TS, Wu FC, Lean ME (2013) Obesity and weight management in the elderly: a focus on men. Best Pract Res Clin Endocrinol Metab 27:509–525CrossRefPubMed

22.

Migliaccio S, Greco EA, Aversa A, Lenzi A (2014) Age-associated (cardio)metabolic diseases and cross-talk between adipose tissue and skeleton: endocrine aspects. Horm Mol Biol Clin Investig 20:25–38PubMed

23.

Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR (2008) Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond) 32:949–958CrossRef

24.

Lobo RA (2008) Metabolic syndrome after menopause and the role of hormones. Maturitas 60:10–18CrossRefPubMed

25.

Polotsky HN, Polotsky AJ (2010) Metabolic implications of menopause. Semin Reprod Med 28:426–434CrossRefPubMed

26.

Kristensen K, Pedersen SB, Vestergaard P, Mosekilde L, Richelsen B (1999) Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women. J Endocrinol 163:55–62CrossRefPubMed

27.

Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR (2001) Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 39:125–132CrossRefPubMed

28.

Spiro AS, Khadem S, Jeschke A, Marshall RP, Pogoda P, Ignatius A, Amling M, Beil FT (2013) The SERM raloxifene improves diaphyseal fracture healing in mice. J Bone Miner Metab 31:629–636CrossRefPubMed

29.

Meli R, Pacilio M, Raso GM et al (2004) Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats. Endocrinology 145:3115–3121CrossRefPubMed

30.

Moran AL, Nelson SA, Landisch RM, Warren GL, Lowe DA (2007) Estradiol replacement reverses ovariectomy-induced muscle contractile and myosin dysfunction in mature female mice. J Appl Physiol 102:1387–1393CrossRefPubMed

31.

Greising SM, Baltgalvis KA, Lowe DA, Warren GL (2009) Hormone therapy and skeletal muscle strength: a meta-analysis. J Gerontol A Biol Sci Med Sci 64:1071–1081CrossRefPubMed

32.

Lowe DA, Baltgalvis KA, Greising SM (2010) Mechanisms behind estrogen’s beneficial effect on muscle strength in females. Exerc Sport Sci Rev 38:61–67CrossRefPubMedPubMedCentral

33.

Messier V, Rabasa-Lhoret R, Barbat-Artigas S, Elisha B, Karelis AD, Aubertin-Leheudre M (2011) Menopause and sarcopenia: a potential role for sex hormones. Maturitas 68:331–336CrossRefPubMed

Title: Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women
Authors: Tomohiko Urano
Masataka Shiraki
Tatsuhiko Kuroda
Shiro Tanaka
Kazuhiro Uenishi
Satoshi Inoue
Publication date: 01-01-2017
Publisher: Springer Japan
Published in: Journal of Bone and Mineral Metabolism / Issue 1/2017
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-015-0733-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Serum pentosidine concentration is associated with radiographic severity of lumbar spondylosis in a general Japanese population

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

Erratum to: Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw

Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment

In vivo expression and regulation of genes associated with vascularization during early response of sutures to tensile force

The role of serum total and free 25-hydroxyvitamin D and PTH values in defining vitamin D status at the end of winter: a representative survey

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page